These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7692816)

  • 1. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
    Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
    Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
    Okamoto M; Okamoto T; Baba M
    Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.
    Rooke R; Tremblay M; Wainberg MA
    Virology; 1990 May; 176(1):205-15. PubMed ID: 1691885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.
    Poli G; Orenstein JM; Kinter A; Folks TM; Fauci AS
    Science; 1989 May; 244(4904):575-7. PubMed ID: 2470148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
    Chong KT; Pagano PJ; Hinshaw RR
    Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
    Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
    In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages.
    Perno CF; Bergamini A; Pesce CD; Milanese G; Capozzi M; Aquaro S; Thaisrivongs S; Tarpley WG; Zon G; D'Agostini C
    J Infect Dis; 1993 Nov; 168(5):1148-56. PubMed ID: 8228348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line.
    Bryant ML; Ratner L; Duronio RJ; Kishore NS; Devadas B; Adams SP; Gordon JI
    Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2055-9. PubMed ID: 2006142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
    Chokekijchai S; Shirasaka T; Weinstein JN; Mitsuya H
    Antiviral Res; 1995 Sep; 28(1):25-38. PubMed ID: 8585758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 proteinase is required for synthesis of pro-viral DNA.
    Baboonian C; Dalgleish A; Bountiff L; Gross J; Oroszlan S; Rickett G; Smith-Burchnell C; Troke P; Merson J
    Biochem Biophys Res Commun; 1991 Aug; 179(1):17-24. PubMed ID: 1652947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
    Cox S; Koshida R; Harmenberg J; Wahren B
    Adv Enzyme Regul; 1991; 31():85-97. PubMed ID: 1715118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
    Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
    Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
    Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
    Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.
    Fujihashi T; Hara H; Sakata T; Mori K; Higuchi H; Tanaka A; Kaji H; Kaji A
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2000-7. PubMed ID: 8540706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages.
    Perno CF; Aquaro S; Rosenwirth B; Balestra E; Peichl P; Billich A; Villani N; Caliò R
    J Leukoc Biol; 1994 Sep; 56(3):381-6. PubMed ID: 8083612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.